ARA-290 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 7 published studies are one click away.
Human trials Repair Also called cibinetide, pHBSP, pyroglutamate helix B surface peptide
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Trial data and community guides agree on 4 mg once a day for 28 days, with community ranges of 1 to 4 mg. The amounts come from phase 2 trials, not a label.
- Half-life
- Not on the site yet, being checked
- How it is taken
- subcutaneous injection
- How long people use it
- 28 days in most trials. The longest human course was 12 weeks.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 1 mg | 20 units 0.20 mL | once a day | 1 mg once a day, the lowest trial arm | 10 days |
| Typical [2] | 4 mg | 80 units 0.80 mL | once a day | 4 mg once a day for 28 days, the dose that worked best in trials | 2 days |
Good to know
- Also called cibinetide.
- An 8 mg daily arm did no better than 4 mg.
- Trials were in nerve pain from sarcoidosis and in diabetes.
- Never approved. Development stopped after the drug company shut down.
Sources for these amounts
- Starting: BioSpace, cibinetide phase 2b sarcoidosis results · Outliyr, ARA-290 report
- Typical: BioSpace, cibinetide phase 2b sarcoidosis results · Outliyr, ARA-290 report
How long people use it: Outliyr, ARA-290 report · BioSpace, cibinetide phase 2b sarcoidosis results
Take the ARA-290 chart with you
Get a one-page printable chart for ARA-290, with the syringe units for each vial and water mix. We can also email you when a new ARA-290 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 7 published studies
Amounts given to people in studies
How it was given: Under the skin, once a day (one early trial used 2 mg IV three times a week)
4 mg was the dose that worked best in the dose-finding trial. Trials were small and short.
Amounts given to animals in studies
Read this first. Human trials used flat mg doses, animal studies used µg per kg. Most trials were run with the company developing it. Studied for nerve damage, not general use.
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 23168581Heij et al, Mol Med 2012 | Human, randomized, 22 sarcoidosis patients with nerve pain (12 active) | 2 mg | IV | Three times a week | 4 weeks | Nerve symptom score improved vs placebo. No safety concerns |
| PMID 24136731Dahan et al, Mol Med 2013 | Human, placebo-controlled, sarcoidosis patients with small nerve fiber loss | Not stated in the abstract | Under the skin | Once a day | 28 days | Nerve symptoms improved, more corneal nerve fibers, longer 6-minute walk |
| PMID 25387363Brines et al, Mol Med 2015 | Human, phase 2, type 2 diabetes with painful neuropathy | 4 mg | Under the skin | Once a day | 28 days, then 1 month follow-up | HbA1c and lipids improved, nerve pain score improved |
| PMID 28475703Culver et al, Invest Ophthalmol Vis Sci 2017 | Human, randomized phase 2b, 64 sarcoidosis patients | 1, 4 or 8 mg/day | NOT IN ABSTRACT | Once a day | 28 days | 4 mg raised corneal nerve fiber area. 1 mg and 8 mg did not reach significance |
| PMID 32674280Lois et al, J Clin Med 2020 | Human, open phase 2, 9 patients with diabetic macular edema | 4 mg/day | Under the skin | Once a day | 12 weeks | Safe. No gain in vision or retinal thickness overall |
| PMID 21873879Swartjes et al, Anesthesiology 2011 | Rat and mouse, nerve injury pain model (n=8 per group) | 30 mcg/kg | Into the belly | Five doses 2 days apart, then once a week | Up to 15 weeks | Long-lasting relief of touch and cold pain. No effect in mice lacking the beta-common receptor |
| PMID 24529189Swartjes et al, Mol Pain 2014 | Rat, nerve injury pain model | 3, 10, 30 and 60 mcg/kg | NOT IN ABSTRACT | Days 1, 3, 6, 8 and 10 | 5 doses, followed 20 weeks | Dose-dependent pain relief for up to 20 weeks, less spinal mcglia activity |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of ARA-290 were used in human studies?
In the studies listed here, people were given from 1 mg once a day for 28 days (sarcoidosis patients) up to 8 mg once a day for 28 days (sarcoidosis patients). The amount used most often was 4 mg under the skin once a day for 28 days. These are what study teams chose for their participants under supervision.
Where do these ARA-290 numbers come from?
From 7 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
Is this a recommendation for how much ARA-290 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.